Payment overview · 2025
General Payments
$633.39
29 reported records · 17 companies
Healthcare provider profile · identity verified
Jacob Hostetler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GROVE, OK · NPI 1265829485
Verified facts
What the public records show
CMS Open Payments records show Jacob Hostetler, M.D. received $633.39 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.86 | 26.8% | 4 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $57.50 | 9.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.49 | 7.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.10 | 6.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.24 | 6.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.25 | 5.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.46 | 5.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.13 | 5.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.07 | 4.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.98 | 3.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.58 | 3.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.07 | 3.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.77 | 3.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.27 | 2.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $17.82 | 2.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.19 | 2.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.61 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $633.39 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.43 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.97 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $57.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.49 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.75 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 226 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 118 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 66 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 22 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 119 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
118 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
119 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
226 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1007 | 297 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 848 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 701 | 171 |
| Lisinopril | Lisinopril | 571 | 163 |
| Losartan Potassium | Losartan Potassium | 549 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 138 |
| Gabapentin | Gabapentin | 450 | 148 |
| Pantoprazole Sodium | Pantoprazole Sodium | 426 | 130 |
| Potassium Chloride | Potassium Chloride | 386 | 124 |
| Furosemide | Furosemide | 361 | 119 |
| Tamsulosin Hcl | Tamsulosin Hcl | 351 | 110 |
| Zolpidem Tartrate | Zolpidem Tartrate | 333 | 58 |
| Omeprazole | Omeprazole | 332 | 108 |
| Tramadol Hcl | Tramadol Hcl | 324 | 84 |
| Metformin Hcl | Metformin Hcl | 300 | 94 |
| Montelukast Sodium | Montelukast Sodium | 299 | 83 |
| Trazodone Hcl | Trazodone Hcl | 294 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 92 |
| Meloxicam | Meloxicam | 284 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 277 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 270 | 101 |
| Prednisone | Prednisone | 260 | 179 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 74 |
| Pregabalin | Pregabalin | 228 | 31 |
| Eliquis | Apixaban | 226 | 43 |
| Carvedilol | Carvedilol | 206 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 60 |
| Allopurinol | Allopurinol | 197 | 56 |
| Sertraline Hcl | Sertraline Hcl | 185 | 45 |
| Simvastatin | Simvastatin | 177 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 47 |
| Baclofen | Baclofen | 155 | 62 |
| Atenolol | Atenolol | 154 | 42 |
| Alprazolam | Alprazolam | 153 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 150 | 21 |
| Famotidine | Famotidine | 147 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 138 | 25 |
| Glipizide | Glipizide | 136 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 134 | 56 |
| Ondansetron Hcl | Ondansetron Hcl | 132 | 70 |
| Lorazepam | Lorazepam | 127 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 119 | 33 |
| Farxiga | Dapagliflozin Propanediol | 118 | 31 |
| Finasteride | Finasteride | 117 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 32 |
| Ozempic | Semaglutide | 115 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 110 | 81 |
| Spironolactone | Spironolactone | 110 | 45 |
| Warfarin Sodium | Warfarin Sodium | 106 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 32 |
| Memantine Hcl | Memantine Hcl | 99 | 24 |
| Temazepam | Temazepam | 99 | 12 |
| Ezetimibe | Ezetimibe | 96 | 29 |
| Buspirone Hcl | Buspirone Hcl | 93 | 28 |
| Clonazepam | Clonazepam | 90 | 15 |
| Jardiance | Empagliflozin | 89 | 25 |
| Myrbetriq | Mirabegron | 88 | 11 |
| Azithromycin | Azithromycin | 86 | 74 |
| Topiramate | Topiramate | 85 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 35 |
| Diazepam | Diazepam | 82 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 80 | 19 |
| Donepezil Hcl | Donepezil Hcl | 78 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 51 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 74 | 25 |
| Celecoxib | Celecoxib | 74 | 19 |
| Januvia | Sitagliptin Phosphate | 74 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 61 |
| Alendronate Sodium | Alendronate Sodium | 70 | 28 |
| Levofloxacin | Levofloxacin | 70 | 58 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 17 |
| Gemtesa | Vibegron | 66 | 15 |
| Levetiracetam | Levetiracetam | 65 | 13 |
| Mirtazapine | Mirtazapine | 63 | 19 |
| Ondansetron Odt | Ondansetron | 63 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 18 |
| Trulicity | Dulaglutide | 61 | 12 |
| Clonidine Hcl | Clonidine Hcl | 60 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 14 |
| Estradiol | Estradiol | 59 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 26 |
| Xarelto | Rivaroxaban | 56 | 16 |
| Enalapril Maleate | Enalapril Maleate | 55 | 17 |
| Cephalexin | Cephalexin | 54 | 44 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 12 |
| Azelastine Hcl | Azelastine Hcl | 52 | 31 |
| Chlorthalidone | Chlorthalidone | 51 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 12 |
| Fluconazole | Fluconazole | 50 | 37 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 49 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 13 |
| Propranolol Hcl | Propranolol Hcl | 44 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Bumetanide | Bumetanide | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 14 |
| Primidone | Primidone | 43 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 12 |
| Acyclovir | Acyclovir | 38 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 14 |
| Bupropion Xl | Bupropion Hcl | 37 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Nystatin | Nystatin | 36 | 19 |
| Valsartan | Valsartan | 36 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 13 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Belsomra | Suvorexant | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 18 |
| Risperidone | Risperidone | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 15 |
| Naproxen | Naproxen | 23 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 11 |
| Mupirocin | Mupirocin | 21 | 13 |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 11 |
| Metolazone | Metolazone | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | 11 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 13 |
| Lactulose | Lactulose | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Febuxostat | Febuxostat | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $633.39 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, ELIQUIS, FARXIGA, GEMTESA, INTERSTIM, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, Quviviq, REPATHA, Rybelsus, Senza, TRELEGY ELLIPTA, TRINTELLIX, VOQUEZNA, VRAYLAR, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error